Synopsis:
Sakar Healthcare has secured its 3rd and 4th EU approvals for oncology injections, namely Carboplatin and Docetaxel, approved in Bulgaria and Bosnia. This made the stock jump by 5% approximately today
The shares of this leading pharmaceutical company are in focus after receiving further approval for its injection to treat cancer and other illnesses. In this article, we will dive more into the details.
With a market capitalisation of Rs 795 crore, the shares of Sakar Healthcare Ltd are currently trading at Rs 362 per share, down by 5 percent from its 52-week high of Rs 380.80 per share. Over the past five years, the stock has delivered a robust return of 556 percent.
On Wednesday, the company, through a stock exchange filing, announced that the company has received the receipt of two more marketing authorisations (MA) of Oncology Injection for the European Union, taking the total count to four MAs.
The names of the two dossiers include Carboplatin and Docetaxel, which have fetched their respective approvals from Bulgaria and Bosnia. It mentioned that the earlier products were used to treat breast cancer, non-small cell lung cancer, prostate cancer and colorectal cancer. However, with the latest authorization for Carboplatin, it will be used to treat ovarian, lung cancer along with other solid tumours.
Marketing Authorization (MA) in the pharmaceutical industry is the official approval granted by a regulatory authority (like the European Medicines Agency or USFDA) to a company to market and sell a specific drug in a particular country or region.
Financial Highlights
Sakar Healthcare reported a revenue growth of 16 percent to Rs 178 crores in FY25 from Rs 153 crores in FY24. Its net profit surged by 50 percent to Rs 18 crores in FY25 from Rs 12 crores in FY24.
The stock delivered an ROE and ROCE of 6.40 percent and 8.58 percent, respectively, and is currently trading at a high P/E of 45.43x as compared to its industry average of 33.63x.
Sakar Healthcare Limited is a pharmaceutical company based in India that focuses on researching, manufacturing, and marketing a diverse array of medicines. Their product lineup includes tablets, capsules, syrups, injections, and dry powders, catering to various health needs like pain relief, infections, mental health, digestion, and more. They also export their products to regions including Southeast Asia, Africa, the MENA area, and the United States.
Written by Satyajeet Mukherjee
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
